CNTX · Context Therapeutics Inc. · Financials

$0.37 -0.01 (-1.38%)

Russell 2000 member Rebalance outlook locked

Market Cap

$34.57M

91.88M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Net Income

-$36.12M -35.2%

FY2025

Diluted EPS

-$0.38 +17.4%

FY2025

Operating Cash Flow

-$26.39M -81.3%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Net Interest Income	—	—	—	$2.46M	—	—	$1.16M	$547.27K	-$64.24K	—
Research & Development	+65.0%	+81.0%	—	$40.11M	$31.86M	$22.7M	$17.78M	$7.09M	$3.81M	$1.64M
General & Administrative	+0.2%	+53.2%	—	$8.62M	$7.85M	$7.22M	$7.29M	$7.79M	$3.63M	$930.67K
Depreciation & Amortization	+20.6%	—	—	$19.47K	$16.25K	$10.88K	$12.04K	$9268	$0	—
Operating Income	—	—	—	-$48.73M	-$39.7M	-$29.92M	-$25.07M	-$15.38M	-$10.53M	-$2.57M
Interest Expense	—	—	—	—	—	—	—	—	$64.24K	$661.22K
Interest Income	—	—	—	$2.46M	$3.38M	$3.2M	$1.16M	—	—	—
Other Non-Operating Income	—	—	—	$313.52K	$200.47K	-$1428	-$55.57K	-$2004	$123.87K	$0
Income Tax	—	—	—	—	$0	$0	$0	$0	$0	$0
Net Income	—	—	—	-$45.96M	-$36.12M	-$26.73M	-$23.96M	-$14.84M	-$10.46M	$6.64M
Net Income Available to Common Stockholders	—	—	—	—	—	—	—	—	-$10.46M	$1.07M
EPS (Basic) USD/shares	—	—	—	-$0.48	-$0.38	-$0.46	-$1.50	-$0.93	-$3.69	$3.07
EPS (Diluted) USD/shares	—	—	—	-$0.48	-$0.38	-$0.46	-$1.50	-$0.93	-$3.69	-$3.96
Shares Outstanding (Basic Avg) shares	+81.3%	+207.1%	—	—	95.19M	58.42M	15.97M	15.97M	2.83M	348.37K
Shares Outstanding (Diluted Avg) shares	+81.3%	+115.4%	—	—	95.19M	58.42M	15.97M	15.97M	2.83M	2.05M

Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 7.12×

EV/EBIT

—

P/E (TTM)

—

Peer median 2.80×

Peer medians compare against the 267 similar-size Biotechnology companies (of 537 listed).

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024
Reportable Segment	-$39,702,631	-$29,923,900

Key facts CIK 1842952 CUSIP 21077P108 13F (30d) 64 filings 64 filers Visit website Investor relations